Will GDUFA III Curtail Priority Assessments?
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.
You may also be interested in...
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.